Cancers Triggered in Less than 1 Year? Learn More at the Friday May 1 – HarrisMartin’s
Genetics and epigenetic issues continue to knock open doors in toxic tort litigation. An example? A recent federal MDL ruling rejected defense Daubert motions seeking to strike expert opinions that were based on the concept of a cancer arising less than 1 year. How could that happen? Think epigenetic actions that “turn on” a cell receptor and leave it generating proteins at full throttle, and putting the cell into an agitated state in which it more easily transforms into a malignant cell.
I will be covering those issues and more on a panel with Lenn Murelle, a smart scientist who runs a company known as Venebio Group. Lenn “gets” molecular science and toxic tort litigation.
2:15 p.m. – 3:15 p.m.
Molecular Epidemiology, Epigenetics, and Nutrigenomics Bioscience – Intersections with Toxic Tort Claims
• Molecular Epidemiology and Toxic Tort Intersections • What is Happening in the Human Body with the Increases in Obesity? • Mesothelioma – Seeing the Intersections with BAP1 Mutation and Epigenetic Factors • Epigenetics and Multi-Generational Toxic Tort Claims
Edward L. Murrelle, MSPH, Ph.D., Co-Founder and CEO, Venebio Group, LLC, Richmond, VA Kirk T. Hartley, LSP Group LLC
Other panels also include real scientists who are at the front edge and also “get” the changes that will transform litigation over the next 20 years. For example, Len van Zyl and his company (ArrayXpress) are way ahead of most and actually are doing genomic testing in toxic tort cases.
9:00 a.m. – 10:00 a.m.
The Rapid Evolution of Law With Quantitative Precision Science
Len van Zyl, Ph.D., CEO and CSO, ArrayXpress, Inc., Raleigh, NC Michael Zapata III, Executive Chairman, ArrayXpress, Inc., Raleigh, NC
10:00 a.m. – 10:45 a.m.
Understanding The Application of Epidemiology to the Science of Genomics
David G. Hoel, Ph.D., Exponent, Inc., Alexandria, VA
11:00 a.m. – 12:00 p.m.
The Role of Medical Toxicology and Ethical Issues
D. Mark Jackson, Bassi Edlin Huie & Blum LLP, San Francisco John B. Sullivan, M.D., MBA, University of Arizona, Department of Emergency Medicine/Medical Toxicology Division, Tucson, AZ (Retired)